Perfect. Hi, everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team at JP Morgan. Today I have the Bruker team with me. This session will start off with a 20-25-minute presentation, followed by 20 to, you know, 15 minutes of Q&A. With that, I have Frank to kick it off with their presentation. Thank you.
Thank you very much, Rachel, for having us here. Thank you to all of you to braving the elements and coming here somehow this morning at this early hour. I'm. Our CFO, Gerald Herman, is here. Our president of our Bruker NANO business, Mark Munch, they will also be joining Q&A in one-on-ones. If you have any questions about IR, our senior director, Justin Ward's in the audience. I'd like to acknowledge two of our board members, Bonnie Anderson and Adelene Perkins. Thank you for joining us. Good to see so many of you here. Let me jump right in. This will be more of an update presentation. It's not really an overview of Bruker. If you're really new to the story, we'll happy to take the time and walk you through it, but this is more of an update.
We are not pre-announcing really results, but we're gonna give a little bit of directional color on Q4 and where we think 2023 is going, 'cause I'm sure you're interested in that. Therefore, I'd like to draw your safe harbor statement, and also it has some language about it that we are giving some color on Q4, which is of course, preliminary because we're really announcing our Q4 results, and we'll get and give formal guidance for 2023. We expect to do that in early to mid-February. A bit of a review. Year to date, the actual reported results up to the third quarter, had very good organic growth with solid margin expansion. We're very pleased with that. If on the left-hand side, if you take a look at that, you...
As a reminder perhaps, despite the fact that in 2021, we had 19% organic growth, so this isn't exactly an easy comparison or something like that. In Q3 year to date, the first three quarters of the year, we had over 10% organic growth. Very pleased also, I think this is an important number, usually we don't highlight it as much. Our gross margin, our non-GAAP gross margin expansion has been well over 100 bips, actually about 160 bips. While our operating margin expansion is also quite satisfactory at 80 bips. It's actually a message in there that shows you that we're really making continued, very significant and thoughtful and intentional investments in our Project Accelerate 2.0 initiatives. I'll talk more about that in a moment.
There, of course, in R&D, but also in marketing and sales in particular. Very good progress year to date. Q4 2022 preliminary revenue estimates, not with numbers, but just directional and a bit of a 2023 outlook. Our preliminary revenue estimate for Q4 2022 is mid to high single digit organic growth. We had given color on our November Q3 earnings call towards, this is subtle, upper mid single digit organic growth. This is mid to high single digit growth, so it's inching up a little bit. Looking at the consensus, we think we'll very comfortably report reported revenue above the consensus. We also see continued solid demand in Q4 2022. For our BSI, remember, that's our Bruker Scientific Instruments segment. That's really the combination of two segments. It's 90% of what we do.
It's what you know us for primarily, life science tools and diagnostics solutions. We again expect book-to-bill also greater than 1, which is quite good for a Q4, because obviously Q4 is always our heaviest revenue quarter. With that, our BSI backlog remains quite high. In fact, it's inching up a little bit. Some of that has to do with continued supply chain constraints. Maybe the worst of the supply chain crisis is over, but sometimes it doesn't feel like it. It's still a struggle to get revenue and everything. But, you know, it's get... I think that will continue at least towards the middle of the year. It is easing a little bit as you probably have heard elsewhere.
That's why our backlog is still inching up and our book-to-bill has remained excellent. With that, more fundamentally, with our strategy, our dual strategy that I'll talk about in a moment, our Project Accelerate 2.0 initiatives plus operational excellence, those really go together. Plus the excellent momentum we've had of 19% and now over, you know, near 10% organic growth for the year. I think our guidance is 8%-10% for the year. For 2023, we actually think we have a strong outlook for 2023. Again, with numbers which will satisfy you more, hopefully we'll intentionally then in early February, but we're looking at mid to high single digit percentage organic revenue growth for 2023. I think that's a really solid setup.
Knowing all the moving pieces and concerns about the economy and all of that, it just shows how well our strategy is working, how desirable our products are, how we're really leveraging our breakout opportunities in proteomics and spatial biology, but also the other Project Accelerate 2.0 initiatives. I'll detail for you a little bit how they're doing organically. I'll give you some examples, but also how we're investing in them inorganically. Lower right-hand corner, If you followed us for years, you'll be particularly surprised by that because we used to be very Europe heavy, right? Europe is still a very strong market for us. A lot of our R&D is in Europe, but we really have very nice balance, and this is particularly because of the fast growth of our U.S. business.
We've grown the fastest and continue to grow the fastest in U.S., in North America, and they're particularly strong growth in biopharma. Both our NMR and our differentiated mass spectrometry proteomics and other tools have been growing tremendously. That's a very nice balance. That's maybe something that not all of you have seen, or if you followed us for years, maybe you have other numbers in mind. Let me continue here. This is our dual strategy. That's sort of the overview slide, although there are a few new things on this page. We continue with our strategy's really working very well and has for a number of years, and it's incrementally evolving and we're refreshing it. It's not stagnant at all.
Our high value innovation, our disciplined entrepreneurial-ism that's part of our culture and really of our formal Bruker management process, drives stronger and stronger revenue growth and also, of course, ultimately non-GAAP EPS growth. Those are our primary objectives from a financial point of view. This all goes along with a long-term commitment, which we've had and which we've delivered and which we will continue to deliver for continued sustainable margin improvements. Big focus on gross margins, continued investments, but also continued operating margin improvements. The two pillars of our strategy are the Project Accelerate 2.0 initiatives, visually captured in that beautiful hexagon that you may have seen. We introduced that in 2017 or 2018. We've really updated that with new elements to the Project Accelerate 2.0. These are the high growth, high margin, initiatives that are...
I'm not gonna list through all of them. Some of them I'll mention today and you can read them. I think of them as pulling up our margins and pulling up our growth rates, and so continued margin expansion, getting into much, much larger TAMs. We've very successfully, in a way, transformed, gradually, but transformed the company and continue to do so towards some very large TAMs. In some areas, particularly in proteomics and spatial biology, we think we have very, very large opportunities. I think we're also leading that transition and in fact, to some extent enabling it, not only surfing the wave, but really also creating it. It's not quite as exciting, but operational excellence in our core business and actually in everything we do, including the new initiatives, is really the other part.
Think of that as pushing up the margins and pushing up the growth rates and of course, being excellent not only in operations logistics, but also on the commercial side in product R&D, driving gross margins. As you know, we're pretty differentiated among the larger players, and that we consistently for many years and expect to continue to have ROIC well above 20%. We're not bad at using capital and investing it. It goes with a differentiated approach to how we grow our business, primarily organically, but also of course, with smart and thoughtful M&A or majority investments. Maybe the only last point on this slide before I move on in the interest of time, in addition to the 6 Project Accelerate initiatives, and for some of these things, you'll get a quick hint today.
Other things are maybe for a future investment, investor day or analyst day if we have one later this year. They are also preparing new high growth, high margin opportunities. They're not completely new and additive. They really emerge from what we're doing in proteomics and spatial biology and in related areas with an important research on cancer research tools. You may have heard that. We've been at AACR meetings and so on, and cancer research pays for a lot of what we're doing. We've been in microbiology for some time. You may be familiar with that, but much bigger push into cancer research. Quite new or relatively new, we've done some of that before, neuroscience research, including the Inscopix and Neurescence acquisitions that I'll talk about in a moment.
This will be a passing remark, we won't have time to talk about it, really also clean tech. Some of you, "Oh, God, Bruker has some industrial business." We have some very good industrial business with very sustainable funding for some of those markets. Clean tech research in a recent press release that may have raised eyebrows, "Wow, we had no idea Bruker is doing that." Yeah. We're... This was for fusion research and for fusion projects, big projects in Europe, in ITER and in China, a big fusion project where we announced in over a short period of time, we had over $50 million of orders. Multi-year deliveries, this won't all be 2023 revenue for fusion research and of course, many other aspects of wind and battery and other research.
In addition to the semiconductor metrology, which has been excellent, continues to be excellent for us. Our industrial research businesses are really very, very healthy. I know that's a concern for this year because there will be a slowdown or a recession. We shall see. I think we're very, very resilient and robust also in that area. Let's talk about proteomics and 4D-proteomics, the proteomics revolution that we are driving and participating in. I mean, this will be a very big decade or two decades for proteomics. I think it will be as important and from a pathology or disease biology research as important or possibly more important than genomics. Genomics is pretty important in all its different flavors of epigenetics and transcriptomics and so on.
At the end of the day, enzymes, that's where the rubber hits the road, and proteomics is important. It was much, much harder to understand, and we're driving that both at the unbiased fundamental research way. We're doing that in tissue, in cell lines, now also much more in plasma. Of course, we're also doing that in targeted proteomics, particular than in when we look at the spatial distributions. I'll come back to that in the spatial biology section. Our timsTOF, which is a very unique proprietary technology that has done really, really well and continues to accelerate. It has now four family members. They're listed here. I won't go through them all. Near the top are the two core proteomics, more and more also now in plasma proteomics, which is very important for us and where we work with various important partners.
also single-cell unbiased proteomics, a pretty unique capability, and this rather flexible instrument that can also do MALDI imaging. That's what you will see when I talk about some of these HiPLEX IHC research panels and tissue multi-omics that can be done on that instrument. Even these $1 million instruments that you see at the bottom, we tend to sell more than 20 of each of them as well, in addition to the core proteomic systems. More than 600 units out there growing very well and really with the fourth dimension, I know it's a technical term, collision cross-section. How's that for a Monday morning? It really makes a big difference. It just allows a much better dissection of the complicated high stack.
It's not only more informative and more differentiated and a deeper look at the proteome and at post-translational modifications, it also actually has turned out to give us greater sensitivity, higher throughput, and higher robustness. Let me give you three stories very briefly. These slides will all be posted later on together with an 8-K and things like that. One of them is from the Technical University of Munich. Bernhard Küster is one of the very well-known pioneers in proteomics. He also does things a little bit differently. He does things with clever chromatography, higher flow rates, microliter flow rates that tend to be very robust, very suitable for clinical applications or high throughput.
The brain proteome is actually one of the tougher proteomes to measure and to do that from FFPE brain tissue and looking at thousands of samples, in this case, at more than 2,000 samples, and he's just getting going. This was sort of a pilot feasibility phase. He had tremendous success. A lot of proteins measured in a very short period of time, half an hour. This is no longer 2-hour measurements and over 9,000 proteins in 13 brain regions. This just wouldn't have been possible. Not to quote, but I'll just read what he says.
He said, "The speed and robustness of the timsTOF HT," that's the latest high throughput version with higher dynamic range, "with our innovative higher flow rates," that's what they're innovating in particular, many other things, "allow our lab to think about projects involving large sample cohorts that simply would have taken too long with previous generations of mass specs." Hanno and Judith Steen at Boston Children's Hospital, they did a large plasma proteomic study on COVID-19 patients, over 4,500 samples, 1,000 patients, some very innovative sample prep bioinformatics. They use this DIA that you may hear. That's again, a bit sort of. Apologize for the technical jargon. That means data independent. That's the hardest way to do mass spectrometry with high throughput and great depth for proteomics on the timsTOF platform.
Again, they, these, they all have other instruments in their labs. They have only adopted timsTOF in recent years, right? The timsTOF platform was critical to our lab completing a demanding study of thousands of samples, something that was not achievable previously, and they're looking forward to larger projects. Let me finish off with a single-cell proteomic example of Professor Nikolai Slavov. He's at Northeastern, an Allen Distinguished Investigator, and is also, I think, getting funded a very sizable focused research organization that he will announce pretty soon. A pioneer in single-cell proteomics, done some fantastic record-breaking work here that's listed above. He is really combining this DIA, this data independent stuff, with multiplexing for higher throughput and in fact, without sacrificing depth and sensitivity. Some very breakthrough work.
He has now two of our single-cell proteomic systems already and is very, very excited and showing how it's clearly outperforming anything else that's out there. In fact, it is an enabling tool. That's what we are. All right. Switching to spatial biology and single-cell omics tissue biology. There is a number of products that go into that. A lot of that is driven by my colleague, Mark Munch, who's also joining us for the Q&A and then later for the one-on-ones. He and his team, the Canopy Biosciences team out of St. Louis, they launched the CellScape instrument. It's a smaller box for one, something less than half a million from Bruker. Can you believe it? It's really a very high throughput walkaway automation with the best performance that's out there.
You all know that single cell and true single cell biology is a very crowded market with a lot of competing claims. We think this is the real thing now with the best performance out there and the best on very high multiplexing. That's what people wanna do in targeted proteomics. Best in class resolution, absolutely single cell, below 0.2 microns resolution, lateral resolution. Very key beyond pretty pictures that everybody sees on the cover of Nature and Cell. You really want to have quantitative biology. We're big believers in that and all of our customers ultimately need quantitative results, including very small cells, small immune cells, maybe with a low expressed protein that may be really very important for maybe your disease biology you're trying to research.
There's a very unique capability, a proprietary high dynamic range that gives us eight orders of magnitude of quantitation, completely unique and really again, I think where the rubber meets the road, along with all the ability to look at much larger fields of view. This is not a sequential technique where you measure one point at a time as some other spatial biology. You measure them as an array all at one time. You can have large fields of view. It's translational and pathology research, and ultimately probably also towards LDTs. This is a fantastic, very important new instrument. In addition to MALDI, Biotyper, and NMR, and timsTOF, remember CellScape. It's gonna be important. However, I have to talk about MALDI for a moment as well.
On the right is more than a $1 million research instrument, of which we sell more than 20 a year. This does it's not single cell, but spatial tissue multi-omics, uniquely combining for the first time. It's a bit of a niche, but a very important niche, where you can combine spatial proteomics with small molecule information. Lipids, metabolites, Glycosylation, glycans. Very important. Very exciting. This is what gets Cell and Nature and Science papers and so on, and some very good fundamental biology research. That's a little bit differentiated, more on the discovery side of spatial biology. I've said a lot of this, so sorry if I'll just let you review that.
In addition to the highest resolution and this very unique ability to quantitate at orders of magnitude more dynamic range, which really is important for biology. The high throughput, the walkaway automation, it's a beautiful instrument. It also, some people really like that you can pick your antibodies that have the best cell activity and integrate them into our workflow. Of course, we also have ready panels for neurological and immuno-oncology and other research. You know, if you're working with mouse antibodies and you want monoclonal, you can use those. If someone also only has a human library, that won't do very much for your research and many other examples.
Usually customers take our libraries, take our kits and then say, "Hey, but I have a few markers that are really dear to me and where I know have very good antibodies. I wanna include that." Enough on that, this is the CellScape ChipCytometry as opposed to mass cytometry instrument. It's going to be very important for Bruker in spatial biology. Here is an example of, pay attention to the small cells that have slow expression levels. Yes, we can see those too, and we see them with absolutely terrific results, something that we have now and that's really impressing a lot of customers. We're doing it with throughput and robustness and automation. Right.
Let me wrap things up in the next, two or three minutes with a bit of an outlook of some of the M&A and majority investment strategy, including some recent M&A transactions that are actually quite important and support both spatial and tissue biology as well as proteomics. Yeah, we do M&A for the right reasons. We're not, we're not one of these core compounders. Others in the industry do that beautifully. We really focus on our Project Accelerate initiatives on driving margins, driving growth, driving EPS of course. M&A often gives us more complete solutions. It allows us to get into adjacent markets where we can leverage our technology if we have some additional software, consumables or automation.
Of course, it's really opened up also some very large markets in cases where we acquire and then further develop a new platform like the CellScape ChipCytometry platform. I'd like to focus on the two breakout areas. proteomics on the left. We acquired a software company, two chromatography and columns companies in the last few years. We also an automation and sample prep company, PreOmics. You heard about that a year ago. Today I'll talk to you about Biognosys, a Swiss specialty company that is really doing fantastic work with specialty high-value CRO services. Rachel, I know you cover CROs.
We're not becoming a CRO company, but we have in some areas in spatial biology and proteomics, we have specialty CRO capabilities that usually also have tools and software, so they enhance our tools portfolio, and they just enable people a lot more... A lot of people would have a budget to buy a timsTOF, maybe they don't have the group or the expertise. They can now go to an expert like Biognosys or some other CRO customers, of course, that we have and can do the great work there. We've also entered with additional platforms, consumables and software. In spatial biology, we've done quite a bit of work, that also is getting us into neuroscience research solutions. Here's Inscopix, we announced that they're here in Mountain View.
They were started by a Stanford electrical engineer who doesn't think molecular, he thinks circuits, and that's actually very, very complementary view of the brain. Inscopix has become a very about $20 million revenue company, excellent margins, excellent growth profiles, highest level of scientific recognition and innovation recognition of having unique solutions for animal model, preclinical, rodent brain circuitry research. Here Francis, none other than Francis Collins, has said, "Look, a big intermediate zone in brain and neuroscience research, we want to understand entire circuits, not only molecules and genes, and not only behavior and functional MRI on the other end." That's exactly that hot area in between that Offers using microscopy, real-life brain circuit microscopy with this solution that you see here.
They've done a great job in not only having a tool or a microscope, but really also the complete solution supporting customers in doing this type of pre-clinical work all the way to data processing and AI. Very much the way we want to approach things with complete life science solutions. They're neuroscience experts. They're not just a bunch of microscopists. They're beautifully done. Last but not least, I'd like to acknowledge Dr. Oliver Rinner, the CEO and co-founder of Biognosys. Thanks for being here today. Biognosys, we've made a majority investment in this company, and we're also doing some additional primary investment to enable them to open a second laboratory in the United States, probably in Massachusetts. They really are a premier company in the proteomics CRO services space.
They also have some very cool tools, the Spectronaut software and various other flavors of that are very, very highly regarded in the industry, highly and broadly used, and among the most innovative. They also tend to bring out the best in our timstalk platform. Yes, we acquired more than 80% very early in January, just last week. Biognosys, just to give you a scaling, about $15 million in revenue. We expect them to grow very fast, particularly with the further push in the U.S. We expect double-digit growth, very strong synergies with our proteomics business. Initially, this will not be accretive yet, but we think it will be accretive to EBIT within 3 years and then have a nice double-digit ROIC. Happy to discuss more details, but I think we're running out of time. It's a terrific company.
It's probably the premier proteomics CRO company out there in terms of experience. Here's a little bit of their background. They've really been at this for a while. They were an ETH spinoff. Ruedi Aebersold, one of the pioneers in proteomics, continues to be a small investor and very supportive. I got a nice email from him the other day. This is just a terrific group and really enhances our proteomics business. Last slide, and I'll stop here. Our strategy, including the Project Accelerate initiatives, is really working. The two breakout opportunities not only give us optimism for 2023, but really for this decade. There are new things where we're more and more going also into new disease areas, neuroscience research, cancer research.
You'll see us becoming more and more differentiated in areas that I think are very, very good for our financial profile. Thank you very much.
Perfect. Thank you so much. Perfect. Now we're going to start the Q&A portion of the session.
I'll stay here and pass any questions on.
Perfect. We do have mic runners in the room. If you want to ask a question, please just raise your hand and someone will pass that off to you. Otherwise, if you are watching via webcast, feel free to submit Q&A through the portal online. Maybe just to kick it off here, Frank, just regarding the order book. Great to hear that you guys beat expectations for 4Q. You exited 3Q with eight months of backlog. You said that the order book grew with B2B over 1 for this most recent quarter. How should we think about that backlog and where it stands today? What is, you know, the right level of order growth for bookings going forward?
Yes, it is, I mean, more typically in the past and pre-pandemic, since then, nothing has really been a typical year, right? Each year has its special idiosyncrasies. We tend to have longer backlog because some of it is our instruments business, but it typically tends to be more, you know, just below six months or something like that. So it being over eight months is unusually long. That's driven by very healthy order book on the one hand, and then, of course, some continued supply chain constraints. Now, that's not all gonna come off in six months. That's gonna come off or, you know, that's gonna come to a lower level eventually. So far it's not happening yet simply because the orders and the momentum are so strong. So it's a problem, but it's a good problem to have.
I expect that that will ease from a number of months in backlog over multiple years, but it does support, of course, a. You know, it gives us an additional, you know, we can sleep at night, and I think we're very well positioned for 2023. We're not just, you know, working off our backlog. We really have continued very strong momentum with our solutions and products.
Great. Maybe if you could just spend a minute talking about supply chain constraints. You said that that was part of the reason why that backlog grew this quarter. How much longer until we're kind of out of the woods on the supply chain and the availability of componentry? Has it improved really, and how much has it improved?
I'll let Mark talk to that. He runs a very big business for Bruker. He's as much in the trenches or more so than I am. So you'll hear from someone else at Bruker.
Mark.
It has improved, but the, you know, the challenges are still there. We, you know, went from a period of, you know, pretty chaotic. We kinda call it a controlled chaos now. You know, new events do occur, but I say less sporadic. The number of sporadic events has dropped. You know, it spans a lot of components. You know, it goes from everybody's kind of knows about the electronic components, you know, the FPGA chips are hard to come by, but it goes into mechanical parts and cable assemblies and a number of things. Those kind of non-chip components are getting better. That's the part that's really we've seen improvement on.
Logistics get better. I mean, half a year ago, we all settled logistics, and you couldn't get trucks, and you couldn't get containers, and you couldn't get flights. That certainly has much improved. Yeah.
Maybe just sticking on the topic of backlog here, can we just talk about cancellations and the risk there? You guys have mentioned that cancellations are really rare, just given the nature of your products and what's required for your customers to really buy and be able to install one of your instruments. Are you still thinking that that's still really low risk, especially with the macro environment? Are you seeing any delays or pushouts of orders? Just what's the general environment look there?
I think it's a very, very minimal risk for us. I mean, you know, sometimes when we have a longer backlog, maybe a customer will elect to buy an instrument where they have an alternative somewhere else. You know, that can happen. You know, everybody else has similar issues as well. Our market share, if anything, it keeps growing. Also in our core areas, not only in the proteomics and spatial biology. Once we have an order, I will acknowledge that every once in a while, a customer tells us, "Ship it a quarter later." From a materiality, it is so immaterial that I regret having said it, but yes. It's really immaterial, and we essentially have no cancellation.
You know, these are just the things that we juggle. An instrument goes into the next quarter, we'll pull something else in, or we got plenty of backlog to do that. The short answer would have been, "Don't worry about it." Literally.
Great.
We got that, we got that. We do that all the time.
Perfect. What about on pricing? Where was pricing exiting 4Q, and how are you thinking about pricing heading into 2023? What's your ability to really reprice some of this backlog that you guys have in the book?
Yeah, we don't reprice the backlog, but obviously we've raised prices. We unfortunately had to, you know, we had to raise prices at least twice in some in the last 12 months or so. Because we have a significant backlog, we had less of a pricing effect. You know, and benefit in margins. We had some pricing benefit in the second half of 2022, but we'll see more of that in 2023. Yeah, we've had very good, you know, desirability of our products, so I don't like that term, but we have pretty good pricing power and, you know, we've just gradually and consistently increased our pricing to where we will have good price realization in addition to unit growth and market share growth.
It's, it comes together much better in 23. In 22, we had a bit of a delay compared to people that have consumables pricing, where they get better pricing, you know, a week later.
Great. Maybe looking at your instrument exposure by geography, that used to be much more heavily weighted towards Europe. Like you mentioned today, it's roughly equal at low 30%. Can you kind of talk about the capital budget standpoint for instruments in both of those geographies? What are you seeing just given the macro environment for both?
See, we'll have to change your research to where you don't call it an exposure, but an opportunity to innovate and drive new fields. That's how we think about it. Being leading with instrument and innovating in new fields like spatial biology or proteomics is a good thing, and then you can pull in the aftermarket. Capital budgets for what we're doing, I mean, capital budgets, you know, it for us, it's always primarily a question of what percentage or part of the budgets get allocated to us.
In life science research and disease biology research, we really are positioned to where our instruments in an NIH budget, in similar budgets via Max Planck Institute in Germany, whatever it might be in China, you name it, are really near the top or at the top of their buying list. We've had good budgets. I assume that some of them will come down a little bit. Even the industrial budgets, most of the stuff we do is not just for capacity buys. In a downturn, that may slow down a little bit. It's been on a fantastic growth pace for us. For instance, in semiconductor, a lot of it is technology buys.
If you look at clean tech, companies will invest from fusion to wind turbines offshore that may need superconducting materials all the way to battery research. They invest in that throughout the cycle. Our cyclicality on our maybe 20% industrial business is very muted. It's not zero. Obviously, that part may be slowing down a little bit this year, at least in terms of orders. Far, we still have very high backlog. Many of our other things that you see in that hexagon are really the funding situation is very good for us.
Great. Maybe a follow-up on that cyclical and industrial exposure. For some of these new markets like semiconductors, can you just talk about what gives you confidence in the resilience of this market, just given you haven't really been through a downturn in some of these more nascent areas? Yeah, just touch on your confidence.
Yeah. Mark, I'll pass that on to you. You drive that business.
Yeah. The confidence is, first of all, long term. If you plot out semiconductor over a decade, it's up and to the right. There are, you know, some things that waver. There are always segments that are quite strong. Frank mentioned, one of the great things about us is we do capacity buys and technology buys. If you look at a lot of semiconductor supplier peers, they're much more weighted towards capacity buys. As companies are trying, our customers are trying to advance a node to get to three nanometer node past, you know, seven to five to three, or to get to higher layer stacks and flash memory, that's where we play quite strongly. Those are more immune to the cycles.
I'd say, and I'll date myself when I say this, Semiconductor is much less cyclical than it used to be. That has to do with the just the diversification of chips and electronics into everything. There's a lot of different forces that drive semi. Yeah.
Great.
Yeah.
Maybe shifting over to biopharma. Can you just talk about your biopharma exposure and really where you play in that market? Bruker's biopharma exposure is, you know, low teens versus some of your peers in the tools group have overinvested in biopharma. How much of it this is an opportunity for you guys, especially given the uptake in timsTOF? You know, how are you gonna be able to differentiate yourself in that market going forward?
We, you know, you may say we're not serving it broadly, but we're serving it in key areas, the timsTOF and proteomics, but also lipidomics, metabolomics. Actually, quite a bit of that type of tissue imaging is being done in pharma, in drug discovery and drug development, even in preclinical areas. Preclinical imaging is strong there. Our NMR business is very strong. It's not only looking at a lot of biological drugs, but we're also small molecule drugs and efficiency and reaction monitoring.
We have many, many, many different islands in biopharma, and that's why that has grown from not so long ago being below 10% of our revenue to now being 15%, 16% and growing very, very rapidly because also proteomics is playing an increasing role, particularly in the U.S. I think in the U.S. last year as we eyeball it, this is probably U.S. biopharma growth. timsTOF and NMR and other tools has been probably the fastest growing area in our company overall. Very, very high double-digit growth. That's in part also part of the reason why we now have this better geographic balance, why the U.S. has grown.
Yes, academic and academic medical research growing tremendously in the U.S. with great funding, with timsTOF, with NMR, and many other tools. Also biopharma research is a big driver of that. Obviously, even larger than in Europe.
Perfect. Maybe spending a minute here on China. China is roughly 15% of your revenues. You had mentioned that some of these semiconductor controls could be a 1%-2% headwind to 2023. Can you just kind of walk us through what you're seeing in that market lately? Is that still on board for that semiconductor headwind? Just with lockdowns, and some of the current outbreaks here, what are you seeing from that market, and how does your confidence stand today for 2023?
The second part, I'll turn over to you, Gerald. The first part, I'll take. I think the No, that's a 1%-2% headwind. We've taken that into account. Of course, last year, we had a 1% or 2% headwind with our Ukraine and Russia business vanishing for obvious reasons and some other special effects. You know, you always have some headwinds, right? Again, we have so many other cylinders of strength that that's all been taken into account. Then maybe from lockdowns to everybody having COVID in China.
Yeah.
It's, it's been good, but maybe you wanna give a little bit more color, Gerald.
Yeah.
Sometimes you're very close with our China office.
Yeah, I spend a lot of time working with our teams in China. I would say this, pretty dynamic environment there historically. This is a major part of our overall business. We've been able to navigate really successfully through not only the lockdowns that occurred a year or so ago, and that's not an easy task, especially around some of the logistics challenges, including servicing some of our instruments. I'd say just more recently, the opening has also created some challenges with the COVID infections. Again, we've got quite a bit of experience in China navigating through these types of issues. We've sorted our way through them in the past. We've got strong instruments, instrument demand in China. Growth is really solid there. Our expectation is that that'll continue to be a major growth market for us.
From biopharma to proteomics, and to spatial biology, the funding priorities in China are similar to what you see from NIH or in Europe or in Japan. Again, strong acknowledging some headwinds, right, in semiconductor. Not all of that, but some of that may take longer approval processes. There is a headwind, but again, you know, we have so many other tailwinds and strong momentum that we just absorb the occasional blow. Every year, there seems to be something, but that's not, you know, that. As I gave some outlook of mid to high single-digit organic growth that we anticipate as a preliminary outlook for 2023, that's all baked in.
Great. Maybe a question here on Alzheimer's and neuro. That's an area that, you know, has been pretty topical with some of the recent data readouts. You guys have been pretty inquisitive when it comes to M&A as well. You did the Inscopix deal, Neurescence. Can you talk to us about how Bruker's product portfolio is positioned today to address that Alzheimer's and neuro research market? How meaningful could this opportunity become over time?
Mark, I'll pass that on to you. Mm-hmm.
Yeah. Yeah, there's a few of them where we participate in neuroscience, and many of them go towards fundamentals of disease understanding, disease discovery. Before Inscopix and Neurescence, we're a big player, in fact, the leader in multiphoton, two-photon technology. We're prominent labs around the world in that. That gave us a strong basis and a good understanding of, you know, where to make our next bet. The next bet was in Inscopix and Neurescence. What that brings, besides the deep brain imaging we already do with multiphoton, is it brings the ability to image the brain and measure brain circuit activity while an animal is freely behaving. It's called naturalistic microscopy.
The importance of that is in therapeutic development, a lot of the animal models are just behavioral, right? You spike a mouse with a drug, and you say, "Does the mouse turn left? Does it turn right?" It's higher in that because behavior is not conserved as you can move over to humans. Brain circuitry is largely conserved. What Inscopix is trying to do is change the paradigm that, you know, your marker, is really is a brain circuit signature. That, there's a lot of great publications coming out of the work that Inscopix is doing with great KOLs.
At a simplistic way, I'd say not this year yet and maybe not next year.
Yeah.
In the neuroscience research tools, including some existing preclinical imaging that we have at Bruker BioSpin already, will be one of our new next $100 million areas.
Perfect. Awesome. With that, you guys, we are out of time. Thank you so much for joining us today.
Thank you so very much for joining us this morning.